Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous Autologous Mesenchymal Stem Cells for Critical Limb Ischemia
DRKS00004192Phase 2Completed
- Sponsor
- Apceth Biopharma
- Start
- Sep 2012
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of autologous mesenchymal stem cells in chronic limb-threatening ischemia (CLTI), peripheral artery occlusion (PAD), sponsored by Apceth Biopharma. Started Sep 2012; status: completed.
02
Drugs
autologous mesenchymal stem cells
03
Conditions
chronic limb-threatening ischemia (CLTI)peripheral artery occlusion (PAD)
Beyond the preview
Go deeper on DRKS00004192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00004192.